search
Back to results

STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.

Primary Purpose

Psychosis, Schizophrenia

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Early Detection (ED)
Usual Detection
Sponsored by
Yale University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Psychosis

Eligibility Criteria

16 Years - 35 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 16 to 35 years old,
  • Within first 3 years of psychosis onset (per pre-defined SOS threshold criteria)
  • Willing travel to local First Episode Service (STEP, New Haven or PREP, Boston) for treatment;
  • Must live in target catchment towns for New Haven site (New Haven, East Haven, West Haven, North Haven, Hamden, Bethany, Orange, Woodbridge, Milford, and Branford) and Boston site (anywhere in Commonwealth of MA)

Exclusion Criteria:

  • Established diagnosis of affective psychotic illness (Bipolar disorder or MDD with psychotic features) or psychosis secondary to substance use or a medical illness
  • Unable to communicate in English
  • IQ<70 or eligible for DDS (Department of Developmental Services) care
  • legally mandated to enter treatment or otherwise unable to give free, informed consent
  • Unable to reliably determine DUP
  • Unstable medical illness

Sites / Locations

  • Yale University
  • Massachusetts Mental Health Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Early Detection (ED)

Usual Detection

Arm Description

This intervention consists of educational campaigns directed at patients & families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis

This intervention will provide equivalent best practice care without the benefit of an early detection campaign

Outcomes

Primary Outcome Measures

Duration of Untreated Psychosis (DUP)
Time from onset of psychosis to first antipsychotic (DUP-Demand); Time from first antipsychotic to enrollment in STEP/PREP (DUP-Supply); Time from onset of psychosis to enrollment in STEP/PREP (DUP-Total)

Secondary Outcome Measures

Levels of social and occupational functioning
A trained assessor will administer the positive and negative syndrome scale (PANSS) scale to every subject for levels of social and occupational functioning. The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The total score is the sum of all scales with a minimum score of 30 and a maximum score of 210.
Change in levels of social and occupational functioning- social
The Global Functioning: Social scale will be used, with symptoms rated 1 (most impaired) to 10 (superior functioning).
Change in levels of social and occupational functioning- roles
The Global Functioning: Role scale will be used, with symptoms rated 1 (most impaired) to 10 (superior functioning).

Full Information

First Posted
February 20, 2014
Last Updated
April 19, 2022
Sponsor
Yale University
Collaborators
Harvard University, National Institute of Mental Health (NIMH)
search

1. Study Identification

Unique Protocol Identification Number
NCT02069925
Brief Title
STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.
Official Title
STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
February 1, 2014 (Actual)
Primary Completion Date
February 27, 2020 (Actual)
Study Completion Date
August 18, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
Harvard University, National Institute of Mental Health (NIMH)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The guiding questions for this study are: can a U.S. adaptation of a successful Scandinavian approach (TIPS) to early detection substantially reduce the duration of untreated psychosis (DUP) and improve outcomes beyond an established first-episode service (FES)? The primary aim of this study is: To determine whether an early detection intervention can reduce DUP in the US, as compared to usual detection. Early detection (ED) will be implemented in one US community (New Haven, CT), and usual detection efforts will continue in another (Boston, MA). DUP will be measured at admission to the corresponding first-episode services (STEP & PREP) in each community, over one year before and throughout ED implementation. The investigators hypothesize that DUP will be reduced significantly in the early detection site compared to the usual detection site; A secondary aim is to determine whether DUP reduction can augment the outcomes of established FES on outcomes in the U.S. The investigators will measure symptoms, functioning and engagement with treatment at entry and over 1 year at each site. The investigators hypothesize that shorter DUP at one FES (STEP) will predict reduced distress and illness severity at entry and better early outcomes at STEP compared to PREP.
Detailed Description
Early detection, or reducing the duration of untreated psychosis (DUP) can substantially ameliorate the distress and disability caused by psychotic illnesses. The TIPS project in Scandinavia used a combination of public and targeted education campaigns coupled with rapid availability of comprehensive services to improve the identification, referral and early treatment of psychotic illness. By targeting the dual 'bottlenecks' of inadequate mental health literacy and delayed access to effective treatment, TIPS significantly reduced DUP2 and experimentally demonstrated improved clinical presentations and outcomes. Effective service models for new onset psychosis exist in the U.S. Multi-element specialty 'first-episode' services (FES), highlighted in this FOA, provide care that is adapted to the specific needs of younger patients and their families and can improve symptoms and functional outcomes during the critical early phase of psychotic illnesses. The NIH-funded Specialized Treatment in Early Psychosis (STEP, New Haven) project, included the first U.S.-based randomized controlled trial to establish the feasibility and effectiveness of a public-sector approach to FES.5 The Prevention and Recovery in Early Psychosis (PREP, Boston) clinic has advanced a similar model of care within an analogous public-academic collaboration. What is required, as the next logical step, is a test of the effectiveness of TIPS' powerful approach to early detection in a policy-relevant U.S. setting, where relatively fragmented pathways to care raise both the challenges and potential public health impact of early detection. The expertise within the investigators investigative team in the design of early detection and the presence of 2 similar, effective, geographically separated and collaborative FES programs (STEP and PREP) presents an excellent opportunity to conduct such a test and thereby advance secondary prevention for psychotic illnesses in the U.S.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Psychosis, Schizophrenia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
285 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Early Detection (ED)
Arm Type
Experimental
Arm Description
This intervention consists of educational campaigns directed at patients & families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis
Arm Title
Usual Detection
Arm Type
Active Comparator
Arm Description
This intervention will provide equivalent best practice care without the benefit of an early detection campaign
Intervention Type
Behavioral
Intervention Name(s)
Early Detection (ED)
Intervention Description
This intervention consists of educational campaigns directed at patients & families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis
Intervention Type
Behavioral
Intervention Name(s)
Usual Detection
Intervention Description
This intervention will provide equivalent best practice care without the benefit of an early detection campaign
Primary Outcome Measure Information:
Title
Duration of Untreated Psychosis (DUP)
Description
Time from onset of psychosis to first antipsychotic (DUP-Demand); Time from first antipsychotic to enrollment in STEP/PREP (DUP-Supply); Time from onset of psychosis to enrollment in STEP/PREP (DUP-Total)
Time Frame
One year before, during campaign and one year after end of campaign
Secondary Outcome Measure Information:
Title
Levels of social and occupational functioning
Description
A trained assessor will administer the positive and negative syndrome scale (PANSS) scale to every subject for levels of social and occupational functioning. The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The total score is the sum of all scales with a minimum score of 30 and a maximum score of 210.
Time Frame
1 year after enrollment in STEP/PREP
Title
Change in levels of social and occupational functioning- social
Description
The Global Functioning: Social scale will be used, with symptoms rated 1 (most impaired) to 10 (superior functioning).
Time Frame
6 months and 12 months
Title
Change in levels of social and occupational functioning- roles
Description
The Global Functioning: Role scale will be used, with symptoms rated 1 (most impaired) to 10 (superior functioning).
Time Frame
6 months and 12 months
Other Pre-specified Outcome Measures:
Title
Change in improved labor market / workforce participation and healthcare utilization
Description
A trained assessor will administer the Services Utilization and Resources Form for Schizophrenia (SURF) instrument to assess workforce participation and other measures relevant to healthcare utilization. The SURF is a multi-item form that uses participants' or caregivers' report to document comprehensively the number, type, and duration of health services and consumption of non-health resources, such as criminal justice events and public assistance
Time Frame
6 months and 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 16 to 35 years old, Within first 3 years of psychosis onset (per pre-defined SOS threshold criteria) Willing travel to local First Episode Service (STEP, New Haven or PREP, Boston) for treatment; Must live in target catchment towns for New Haven site (New Haven, East Haven, West Haven, North Haven, Hamden, Bethany, Orange, Woodbridge, Milford, and Branford) and Boston site (anywhere in Commonwealth of MA) Exclusion Criteria: Established diagnosis of affective psychotic illness (Bipolar disorder or MDD with psychotic features) or psychosis secondary to substance use or a medical illness Unable to communicate in English IQ<70 or eligible for DDS (Department of Developmental Services) care legally mandated to enter treatment or otherwise unable to give free, informed consent Unable to reliably determine DUP Unstable medical illness
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vinod Srihari, MD
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yale University
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06520-8234
Country
United States
Facility Name
Massachusetts Mental Health Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
25023923
Citation
Annamalai A, Palmese LB, Chwastiak LA, Srihari VH, Tek C. High rates of obstructive sleep apnea symptoms among patients with schizophrenia. Psychosomatics. 2015 Jan-Feb;56(1):59-66. doi: 10.1016/j.psym.2014.02.009. Epub 2014 Mar 2.
Results Reference
background
PubMed Identifier
25454802
Citation
Tek C, Palmese LB, Krystal AD, Srihari VH, DeGeorge PC, Reutenauer EL, Guloksuz S. The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trial. Schizophr Res. 2014 Dec;160(1-3):180-5. doi: 10.1016/j.schres.2014.10.002. Epub 2014 Oct 29.
Results Reference
background
PubMed Identifier
25962699
Citation
Tek C, Kucukgoncu S, Guloksuz S, Woods SW, Srihari VH, Annamalai A. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Early Interv Psychiatry. 2016 Jun;10(3):193-202. doi: 10.1111/eip.12251. Epub 2015 May 12.
Results Reference
background
PubMed Identifier
29764759
Citation
Kline ER, DeTore NR, Keefe K, Seidman LJ, Srihari VH, Keshavan MS, Guyer M. Development and validation of the client engagement and service use scale: A pilot study. Schizophr Res. 2018 Nov;201:343-346. doi: 10.1016/j.schres.2018.05.006.
Results Reference
background
PubMed Identifier
28864280
Citation
Kline E, Thomas L. Cultural factors in first episode psychosis treatment engagement. Schizophr Res. 2018 May;195:74-75. doi: 10.1016/j.schres.2017.08.035. Epub 2017 Aug 30.
Results Reference
background
PubMed Identifier
25663602
Citation
van Schalkwyk GI, Davidson L, Srihari V. Too Late and Too Little: Narratives of Treatment Disconnect in Early Psychosis. Psychiatr Q. 2015 Dec;86(4):521-32. doi: 10.1007/s11126-015-9348-4.
Results Reference
background
PubMed Identifier
27691379
Citation
Steiner JL, Anez-Nava L, Baranoski M, Cole R, Davidson L, Delphin-Rittmon M, Dike C, DiLeo PJ, Duman RS, Kirk T Jr, Krystal J, Malison RT, Rohrbaugh RM, Sernyak MJ, Srihari V, Styron T, Tebes JK, Woods S, Zonana H, Jacobs SC. The Connecticut Mental Health Center: Celebrating 50 Years of a Successful Partnership Between the State and Yale University. Psychiatr Serv. 2016 Dec 1;67(12):1286-1289. doi: 10.1176/appi.ps.201600373. Epub 2016 Oct 3.
Results Reference
background
PubMed Identifier
28434615
Citation
Foss-Feig JH, Adkinson BD, Ji JL, Yang G, Srihari VH, McPartland JC, Krystal JH, Murray JD, Anticevic A. Searching for Cross-Diagnostic Convergence: Neural Mechanisms Governing Excitation and Inhibition Balance in Schizophrenia and Autism Spectrum Disorders. Biol Psychiatry. 2017 May 15;81(10):848-861. doi: 10.1016/j.biopsych.2017.03.005. Epub 2017 Mar 14.
Results Reference
background
PubMed Identifier
29328779
Citation
Dixon LB, Goldman HH, Srihari VH, Kane JM. Transforming the Treatment of Schizophrenia in the United States: The RAISE Initiative. Annu Rev Clin Psychol. 2018 May 7;14:237-258. doi: 10.1146/annurev-clinpsy-050817-084934. Epub 2018 Jan 12.
Results Reference
background
PubMed Identifier
27745755
Citation
Starc M, Murray JD, Santamauro N, Savic A, Diehl C, Cho YT, Srihari V, Morgan PT, Krystal JH, Wang XJ, Repovs G, Anticevic A. Schizophrenia is associated with a pattern of spatial working memory deficits consistent with cortical disinhibition. Schizophr Res. 2017 Mar;181:107-116. doi: 10.1016/j.schres.2016.10.011. Epub 2016 Oct 10.
Results Reference
background
PubMed Identifier
24976861
Citation
Breitborde NJ, Kleinlein P, Srihari VH. Causality Orientations among Individuals with First-Episode Psychosis. Psychosis. 2014 Jun 1;6(2):177-180. doi: 10.1080/17522439.2012.762801.
Results Reference
background
PubMed Identifier
25603283
Citation
Hay RA, Roach BJ, Srihari VH, Woods SW, Ford JM, Mathalon DH. Equivalent mismatch negativity deficits across deviant types in early illness schizophrenia-spectrum patients. Biol Psychol. 2015 Feb;105:130-7. doi: 10.1016/j.biopsycho.2015.01.004. Epub 2015 Jan 17.
Results Reference
background
PubMed Identifier
27580422
Citation
Guloksuz S, Li F, Tek C, Woods SW, McGlashan TH, Friis S, Srihari VH. Analyzing the Duration of Untreated Psychosis: Quantile Regression. JAMA Psychiatry. 2016 Oct 1;73(10):1094-1095. doi: 10.1001/jamapsychiatry.2016.2013. No abstract available.
Results Reference
background
PubMed Identifier
28859587
Citation
Wasser T, Pollard J, Fisk D, Srihari V. First-Episode Psychosis and the Criminal Justice System: Using a Sequential Intercept Framework to Highlight Risks and Opportunities. Psychiatr Serv. 2017 Oct 1;68(10):994-996. doi: 10.1176/appi.ps.201700313. Epub 2017 Sep 1.
Results Reference
background
PubMed Identifier
24050720
Citation
Perez VB, Woods SW, Roach BJ, Ford JM, McGlashan TH, Srihari VH, Mathalon DH. Automatic auditory processing deficits in schizophrenia and clinical high-risk patients: forecasting psychosis risk with mismatch negativity. Biol Psychiatry. 2014 Mar 15;75(6):459-69. doi: 10.1016/j.biopsych.2013.07.038. Epub 2013 Sep 16.
Results Reference
background
PubMed Identifier
25471062
Citation
Srihari VH, Tek C, Pollard J, Zimmet S, Keat J, Cahill JD, Kucukgoncu S, Walsh BC, Li F, Gueorguieva R, Levine N, Mesholam-Gately RI, Friedman-Yakoobian M, Seidman LJ, Keshavan MS, McGlashan TH, Woods SW. Reducing the duration of untreated psychosis and its impact in the U.S.: the STEP-ED study. BMC Psychiatry. 2014 Dec 4;14:335. doi: 10.1186/s12888-014-0335-3.
Results Reference
background
PubMed Identifier
26747524
Citation
Srihari VH, Jani A, Gray M. Early Intervention for Psychotic Disorders: Building Population Health Systems. JAMA Psychiatry. 2016 Feb;73(2):101-2. doi: 10.1001/jamapsychiatry.2015.2821. No abstract available.
Results Reference
background
PubMed Identifier
28779850
Citation
Srihari VH. Working toward changing the Duration of Untreated Psychosis (DUP). Schizophr Res. 2018 Mar;193:39-40. doi: 10.1016/j.schres.2017.07.045. Epub 2017 Aug 3. No abstract available.
Results Reference
background
PubMed Identifier
29927083
Citation
Mathis WS, Woods S, Srihari V. Blind Spots: Spatial analytics can identify nonrandom geographic variation in first episode psychosis program enrollments. Early Interv Psychiatry. 2018 Dec;12(6):1229-1234. doi: 10.1111/eip.12681. Epub 2018 Jun 21.
Results Reference
background
PubMed Identifier
30488086
Citation
Kline E, Hendel V, Friedman-Yakoobian M, Mesholam-Gately RI, Findeisen A, Zimmet S, Wojcik JD, Petryshen TL, Woo TW, Goldstein JM, Shenton ME, Keshavan MS, McCarley RW, Seidman LJ. A comparison of neurocognition and functioning in first episode psychosis populations: do research samples reflect the real world? Soc Psychiatry Psychiatr Epidemiol. 2019 Mar;54(3):291-301. doi: 10.1007/s00127-018-1631-x. Epub 2018 Nov 28.
Results Reference
background

Learn more about this trial

STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.

We'll reach out to this number within 24 hrs